Rx Importation Sinks In Senate, But Leaves Anticounterfeiting Regs In Its Wake
Executive Summary
Although the drug importation provisions included in the Senate's version of the FDA Revitalization Act are not expected to create a cross-border trading system, their anticounterfeiting language could still have a significant impact on industry
You may also be interested in...
Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees
Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich
Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees
Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich
e-Pedigree Requirement In Calif. Sets High Hurdle; Pfizer Wants 5 More Years
The Jan. 1, 2009 deadline set by the California Board of Pharmacy mandating the establishment of an e-pedigree system is coming under pressure, with industry telling the state that the requirement of "item-level serialization" is not a realistic goal